The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 412 participants.

Also called NCT01320345

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 412 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01320345
  • ANZCTR ACTRN12611000249954
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Hong Kong SAR China, New Zealand, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT01320345. Randomized; quadruple masking; primary purpose treatment. Start 2016-11-03 (actual); primary completion 2026-08-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
Acronym
FAME 1 EYE
Condition
Type 1 Diabetes Mellitus
Condition
Diabetic Retinopathy
Condition
Diabetic Nephropathies
Intervention (Drug)
Fenofibrate
Intervention (Drug)
Inert lactose placebo
Lead sponsor
University of Sydney (class: other)
Collaborator
National Health and Medical Research Council, Australia (class: other)
Collaborator
Juvenile Diabetes Research Foundation Australia (class: not stated)
Collaborator
Mylan Pharmaceuticals Inc (class: industry)

Record details

Record id
cardio:ct-nct01320345
Content hash
82f9285c2234a19857e074ba8faa7200e13be4a844275c7e4910f76a0001bfaf